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Abstract - Clonal non-malignant hematological 
disorders are a heterogeneous group of diseases that are 
particularly challenging for hematologists. Indeed, most 
obvious and frequent hematological diseases include a broad 
spectrum of malignancies, such as leukemias, lymphomas, 
myeloma, and other myeloproliferative or 
lymphoproliferative disorders.  
 In recent years, all these diseases have been categorized 
by the WHO according to a novel classification of myeloid 
and lymphoid malignancies, which takes in account the 
outstanding progress in our understanding of molecular 
defects underlying hematological malignancies. Regardless 
of a number of novel technologies, hematologists continue to 
deal daily with conditions where a clear diagnosis of a 
malignancy is missing: this is the case of several clonal 
hematological disorders, which are considered bona fide 
non-malignant.  
Some myelodysplastic syndromes, chronic T and NK 
disorders of granular lymphocytes, myelofibrosis, 
monoclonal gammopathies, monoclonal B-cel lymphocytosis, 
mastocytosis and paroxysmal nocturnal hemoglobinuria are 
paradigmatic examples of how clonal disorders are clearly 
different from cancers, even if they may share with 
hematological malignancies similar molecular, genetic, 
epigenetic and immunological processes. Indeed, it is not 
entirely clear whether in individual conditions such 
pathogenic mechanisms may represent initial step(s) of 
malignant transformation, making a bridge between these 
clonal non-malignant disorders and typical hematological 
cancers. Some of these non-malignant disorders imply 
specific pathogenic mechanisms and/or clinical course, and 
so they have been definitely established with their own 
biological and clinical identity. However, the obvious 
question whether some of these clonal non-malignant 
hematological diseases form some a kind of disease-
continuum with their corresponding malignant counterpart 
is still to be answered.  
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This issue of Translational Medicine @ UniSa was 
conceived in the aim of providing a cutting-edge about 
our understanding of pathophysiology, clinical aspects, 
therapeutic strategies and possible malignant evolution of 
these clonal non-malignant hematological disorders. 
Clonal non-malignant hematological disorders have 
continued to shake the thoughts of several researchers [1]. 
Whereas for most non-hematologists clonality implies 
cancer by definition, in hematology clonality seems to be 
associated with physiological of quasi-physiological 
processes. Indeed, recent and old studies have 
documented that hematopoiesis itself can be considered 
less polyclonal then initially thought: in fact, it has been 
demonstrated that even in healthy individuals the active 
hematopoietic stem cell pool (which account for whole 
blood cell production, life-long) should not exceed a few 
hundreds (<500, according to Buesher et al) [2-4]. This 
pool of active hematopoietic stem cells may be even 
smaller in specific circumstances not necessarily 
considered a disease, such as after hematopoietic stem cell 
transplantation [5].  
One of disease discussed in this issue, named 
Paroxysmal Nocturnal Hemoglobinuria, exhibits a unique 
condition where the whole hematopoiesis can be sustained 
life-long by a single hematopoietic stem cells, which quite 
surprisingly does not show over time any exhaustion nor 
malignant transformation [6-7].  
More commonly, oligoclonal hematopoiesis is the 
hallmark of myelodysplastic syndromes (MDSs) and 
other bone marrow failures, and is actually considered a 
first step toward to malignant transformation and possible 
leukemias. However, as extensively discussed in this 
issue, MDSs may sometimes imply pathogenic 
mechanisms which not necessarily include (at least 
initially) an obvious malignant transformation [8-9]. 
Rather, some MDSs may share immune-mediated 
pathogenic mechanisms which are similar to those 
demonstrated in typical immune-mediated bone marrow 
failure (i.e., acquired idiopathic aplastic anemia). In this 
case, oligoclonal hematopoiesis may simply reflect the 
contraction of a stem cell pool which is undergoing an 
extrinsic damage, possibly by the immune system. Even 
in this context, the distinction between external pressure 
and possible intrinsic defects (malignant, or pre-
malignant) is hard: in fact, genetic lesions can be detected 
by either karyotype analysis or more deep molecular 
analysis (up to full-exome sequencing, by next-generation 
sequencing).  
It is intriguing that even in presence of these gene 
mutations it is impossible to establish their actual role in 
the pathophysiology of the disease; in fact, with the 
exception of gene lesions known for their specific 
pathogenic role, most of these genetic defects could be 
detected just for the presence of a clonal hematopoiesis, 
becoming dominant over residual hematopoiesis for 
different reasons (e.g., immune selection, random damage 
of polyclonal hematopoietic stem cells, etc). In other 
words, even a mutation with no pathogenic role (i.e., 
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neutral; as well as any other mutation) may become 
evident (i.e., fixed) just because it occurs in the context of 
an oligoclonal hemopoiesis (this process is often 
described as “neutral fixation”, or “founder effect”). A 
clear evidence supporting this possibility is the 
observation of self-limiting or even transient karyotipic 
abnormalities demonstrated in aplastic anemia [10] or 
even in paroxysmal nocturnal hemoglobinuria [11].   
So if (oligo-)clonality may be considered a possible 
finding in the hematopoietic compartment, without 
necessarily implying the presence of a leukemia, its 
meaning in the context of the immune system is even 
more intriguing. Indeed, acquired or adaptive immunity 
has evolved to improve the protection from pathogens, 
and it is based on the activity of highly specialized cells, 
mostly B and T lymphocytes, which work in a cell-based 
fashion as well as by fluid phase effectors (mostly 
antibodies, but also several cytokines).  
It has to be reminded that the efficiency of acquired 
immunity lies on the possibility of selecting, via somatic 
mutation of specific genes, immune cells with a particular 
specificity for foreign antigens/pathogens. Thus, clonal 
expansion of immune cells (either B or T lymphocytes) is 
a common para-physiological phenomenon which occurs 
daily for an effective protection from pathogens.  
There is a plethora of data demonstrating that both 
humoral or cellular responses against pathogens are clonal 
(for instance after vaccinations), and the ability of 
mounting such clonal responses correlates with the 
efficiency of protection. Thus, it is not surprising if this 
highly regulated mechanism may quite easily run into 
mistakes, leading to the selection of clonal cells which 
can be useless, or even detrimental for the whole 
organism. Given with this background, it is intelligible 
that clonality within the immune system may represent a 
uncontrolled, deranged, immune response, as well, as 
obvious, a cancer of immune cells. Indeed, oligoclonality, 
seen both as the presence of some (auto-)antibodies 
and/or of clonal B or more commonly T cells is 
considered as a surrogate marker of autoimmune 
disorders. In this issue some experts review clonal 
expansions of myeloid cells, plasmacells, B, T and NK 
cells, discussing the problems of differential diagnosis 
with malignancies of these cells [7-9,12-16].  
Once again, they deal with pathogenic mechanisms 
which may share common pathways, finally concluding 
that some clonal conditions should not be considered 
cancers, even if a possible future malignant 
transformation cannot be ruled out.  
Thus, even for the immune system, clonality per se is 
not cancer, but may represent an initial step possibly 
leading to malignant transformation: in other words, 
clonality (seen as the uncontrolled extreme of a 
physiological oligoclonality) may be considered a bridge 
between normal immune response and cancer.  
The observation that lymphoproliferative disorders 
are possibly associated with some common pathogens 
(mostly viruses such as EBV, HBV, HCV, HTLV, HHV8, 
but also Helycobacter Pilorii) is a clear confirmation of 
this possible process, which on the other end remains 
largely unpredictable, given that most antigen-driven 
clonal expansion may persist as non-malignant, possibly 
leading to clinical manifestations which are independent 
from a malignant transformation (e.g., cytopenia of large 
granular lymphocyte expansions, paraprotein-associated 
symptoms, etc.). 
In conclusion most (if not any) cancers are clonal, but 
not all clones are malignant: the reviews included in this 
issue describe different scenarios, and represent a useful 
guide to face the specific topics discussed, but even more 
to a thoughtful and critical view of possible cases that a 






[1] WHO Classification of Tumours of Haematopoietic 
and Lymphoid Tissues, Fourth Edition. Edired by the 
World Health Organization, 2008. 
[2] Buescher ES, Alling DW, Gallin JI. Use of an X-
linked human neutrophil marker to estimate timing of 
lyonization and size of the dividing stem cell pool. J Clin 
Invest 1985;76:1581–1584. 
[3] Shepherd BE, Guttorp P, Lansdorp PM, Abkowitz JL. 
Estimating human hematopoietic stem cell kinetics using 
granulocyte telomere lengths. Exp Hematol 
2004;32:1040–1050. 
[4] Dingli D, Pacheco JM. Ontogenic growth of the 
haemopoietic stem cell pool in humans. Proc Biol Sci 
2007;274:2497–2501. 
[5] Nash R, Storb R, Neiman P. Polyclonal reconstitution 
of human marrow after allogeneic bone marrow 
transplantation. Blood 1988;72:2031–2037. 
[6] Nishimura Ji J, Hirota T, Kanakura Y, Machii T, 
Kageyama T, Doi S, Wada H, Masaoka T, Kanayama Y, 
Fujii H, Inoue N, Kuwayama M, Inoue N, Ohishi K, 
Kinoshita T.Long-term support of hematopoiesis by a 
single stem cell clone in patients with paroxysmal 
nocturnal hemoglobinuria. Blood 2002;99(8):2748-2751. 
[7] Risitano AM. Anti-complement treatment in 
paroxysmal nocturnal hemoglobinuria: where we stand 










Molecular Pathogenesis of Myelodysplastic Syndromes. 
Transl Med UniSa 2013:8. [Epub ahead of print]. 
[9] Serio B, Risitano AM, Giudice V, Montuori N, Selleri 
C. Immunological derangement in Hypocellular 
Myelodysplastic Syndromes. Transl Med UniSa 2013;8: 
31-42 
[10] Maciejewski JP, Risitano A, Sloand EM, Nunez O, 
Young NS. Distinct clinical outcomes for cytogenetic 
abnormalities evolving from aplastic anemia. Blood 
2002;99(9):3129-3135. 
[11] Araten DJ, Swirsky D, Karadimitris A, Notaro R, 
Nafa K, Bessler M, Thaler HT, Castro-Malaspina H, 
Childs BH, Boulad F, Weiss M, Anagnostopoulos N, 
Kutlar A, Savage DG, Maziarz RT, Jhanwar S, Luzzatto 
Translational Medicine @ UniSa - ISSN 2239-9747 2014, 8(1): 1-3 
 
3 
Università degli Studi di Salerno 
L. Cytogenetic and morphological abnormalities in 




A, Tiu RV. Molecular Genetics of 
Myelofibrosis and its associated Disease Phenotypes. 
Transl Med UniSa 2013;8: 53-64 
[13] Magliacane D, Parente R, Triggiani M. Current 
Concepts on Diagnosis and Treatment of Mastocytosis. 
Transl Med UniSa 2013;8: 65-74 
 [14] Palladino C, Bruno B, Boccadoro M. Discovering 
the meaning of monoclonal gammopathy of undetermined 
significance: current knowledge, future challenges. Transl 
Med Unisa 2013;8: 12-18 
[15] D’Arena G, Musto P. Monoclonal B-cell 
lymphocytosis. Transl Med Unisa 2013;8 
[16] Zambello R, Teramo
 
A, Gattazzo C, Semenzato G. 
Are T-LGL leukemia and NK-chronic Lymphoproli-
ferative disorders really two distinct diseases? Transl Med 
UniSa 2013:8: 4-11 
 
 
  
 
